Heron Therapeutics Reaches Settlement Agreement with Mylan for CINVANTI and APONVIE Patent Disputes Heron Therapeutics has reached a settlement with Mylan regarding patent disputes over CINVANTI and APONVIE. Mylan can market generics starting June 2032.

Heron Therapeutics Reaches Settlement Agreement with Mylan for CINVANTI and APONVIE Patent Disputes #United_States #CARY #CINVANTI #Heron_Therapeutics #Mylan_Pharmaceuticals

Heron Therapeutics Reports Financial Achievements and Strategic Developments for 2024 Heron Therapeutics has released its financial report for Q4 and the full year 2024, showcasing key developments and growth strategies for future success.

Heron Therapeutics Reports Financial Achievements and Strategic Developments for 2024 #USA #CINVANTI #Heron_Therapeutics #Cary,_North_Carolina #ZYNRELEF

Heron Therapeutics Wins Patent Case for CINVANTI® Against Fresenius Kabi USA Heron Therapeutics celebrates a crucial victory as U.S. District Court validates its CINVANTI® patents, blocking Fresenius Kabi's generic version.

Heron Therapeutics Wins Patent Case for CINVANTI® Against Fresenius Kabi USA #United_States #San_Diego #CINVANTI #Heron_Therapeutics #Fresenius_Kabi